A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies.
A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies.
复制标题
DOI：
10.1186/s12929-022-00852-9
复制
发表时间：
2022-09-12
影响因子：
11
通讯作者：
Wu, Han-Chung
中科院分区：
文献类型：
--
作者：
Kumari, Monika;Lu, Ruei-Min;Li, Mu-Chun;Huang, Jhih-Liang;Hsu, Fu-Fei;Ko, Shih-Han;Ke, Feng-Yi;Su, Shih-Chieh;Liang, Kang-Hao;Yuan, Joyce Pei-Yi;Chiang, Hsiao-Ling;Sun, Cheng-Pu;Lee, I-Jung;Li, Wen-Shan;Hsieh, Hsing-Pang;Tao, Mi-Hua;Wu, Han-Chung
关键词：
新型冠状病毒病(新冠肺炎)大流行仍然是一种全球公共卫生危机，带来了广泛的挑战。为了帮助解决一些主要问题，科学界设计了针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染的疫苗、诊断工具和治疗方法。技术发展的快速步伐，特别是在疫苗方面，是一项令人震惊的历史性科学成就。然而，仍有许多挑战需要克服，例如改进SARS-CoV-2新出现突变株的疫苗和药物治疗效果。更具传染性的变种的爆发继续削弱了现有疫苗和药物的效用。因此，疫苗和药物对最新变种的有效性是支持最新监管决策的临床数据持续分析的主要考虑因素。获得紧急使用授权(EUA)的前两种疫苗BNT162b2和mRNA-1273对当前最广泛的SARS-CoV-2变异株Omicron仍显示出60%以上的保护效力。这种变体在刺突蛋白中携带30多个突变，这在很大程度上消除了治疗性抗体的中和作用。幸运的是，一些中和抗体和抗病毒药物治疗已经显示出持续的临床疗效。在这篇综述中，我们提供了一个框架，用于了解正在进行的不同类型疫苗和疗法的开发努力，包括小分子和抗体药物。总结了新出现的变种的连锁反应，包括疫苗的更新和药物再利用的努力。此外，我们总结了支持开发和分发针对SARS-CoV-2毒株的疫苗、小分子药物和具有广谱活性的治疗性抗体的临床试验。网上版载有补充材料，可在10.1186/s12929-022-00852-9查阅。
The novel coronavirus disease (COVID-19) pandemic remains a global public health crisis, presenting a broad range of challenges. To help address some of the main problems, the scientific community has designed vaccines, diagnostic tools and therapeutics for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The rapid pace of technology development, especially with regard to vaccines, represents a stunning and historic scientific achievement. Nevertheless, many challenges remain to be overcome, such as improving vaccine and drug treatment efficacies for emergent mutant strains of SARS-CoV-2. Outbreaks of more infectious variants continue to diminish the utility of available vaccines and drugs. Thus, the effectiveness of vaccines and drugs against the most current variants is a primary consideration in the continual analyses of clinical data that supports updated regulatory decisions. The first two vaccines granted Emergency Use Authorizations (EUAs), BNT162b2 and mRNA-1273, still show more than 60% protection efficacy against the most widespread current SARS-CoV-2 variant, Omicron. This variant carries more than 30 mutations in the spike protein, which has largely abrogated the neutralizing effects of therapeutic antibodies. Fortunately, some neutralizing antibodies and antiviral COVID-19 drugs treatments have shown continued clinical benefits. In this review, we provide a framework for understanding the ongoing development efforts for different types of vaccines and therapeutics, including small molecule and antibody drugs. The ripple effects of newly emergent variants, including updates to vaccines and drug repurposing efforts, are summarized. In addition, we summarize the clinical trials supporting the development and distribution of vaccines, small molecule drugs, and therapeutic antibodies with broad-spectrum activity against SARS-CoV-2 strains. The online version contains supplementary material available at 10.1186/s12929-022-00852-9.
登录
查看更多内容
DOI：
10.1056/nejmoa2119451
发表时间：
2022-04-21
期刊：
The New England journal of medicine
影响因子：
--
作者：
Andrews N;Stowe J;Kirsebom F;Toffa S;Rickeard T;Gallagher E;Gower C;Kall M;Groves N;O'Connell AM;Simons D;Blomquist PB;Zaidi A;Nash S;Iwani Binti Abdul Aziz N;Thelwall S;Dabrera G;Myers R;Amirthalingam G;Gharbia S;Barrett JC;Elson R;Ladhani SN;Ferguson N;Zambon M;Campbell CNJ;Brown K;Hopkins S;Chand M;Ramsay M;Lopez Bernal J
通讯作者：
Lopez Bernal J
影响因子：
3.7
作者：
Anand P;Stahel VP
通讯作者：
Stahel VP
影响因子：
64.8
作者：
BRENNER, S;MESELSON, M;JACOB, F
通讯作者：
JACOB, F
REGN-COV2抗体预防和治疗恒河猕猴和仓鼠中的SARS-COV-2感染。
DOI：
10.1126/science.abe2402
发表时间：
2020-11-27
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Baum A;Ajithdoss D;Copin R;Zhou A;Lanza K;Negron N;Ni M;Wei Y;Mohammadi K;Musser B;Atwal GS;Oyejide A;Goez-Gazi Y;Dutton J;Clemmons E;Staples HM;Bartley C;Klaffke B;Alfson K;Gazi M;Gonzalez O;Dick E Jr;Carrion R Jr;Pessaint L;Porto M;Cook A;Brown R;Ali V;Greenhouse J;Taylor T;Andersen H;Lewis MG;Stahl N;Murphy AJ;Yancopoulos GD;Kyratsous CA
通讯作者：
Kyratsous CA
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group